Kathy L. McGraw

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 460 citations · Full text

Medicine, Oncology, Pharmacology +5

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

Andrés Jerez, Michael J. Clemente, Hideki Makishima et al. · Blood · 2012 · 418 citations · Full text

Medicine, Hematology, Molecular Genetics +13

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu et al. · Blood · 2016 · 346 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

David A. Sallman, Rami S. Komrokji, Christine Vaupel et al. · Leukemia · 2015 · 231 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

David A. Sallman, Amy F. McLemore, Amy L. Aldrich et al. · Blood · 2020 · 188 citations · Full text

Medicine, Hematology, Molecular Genetics +13